SBIR Phase II: A Novel Bacteriophage Mutant as a Platform Carrier for Next Generation Vaccines

小型企业创新研究(SBIR)第二阶段项目更广泛的影响/商业潜力是对结合疫苗领域的贡献，结合疫苗为公共卫生做出了革命性的巨大贡献。成功开发后，拟议的平台将可供生物技术和制药公司用于开发针对包括癌症和新出现的传染病在内的各种抗原的下一代结合疫苗，以改善临床结果。除了疫苗外，该平台还为基础科学研究和治疗应用提供了产生单克隆抗体的良好起点。这个小型企业创新研究第二阶段项目旨在建立一种拟议的基于突变噬菌体的载体平台的适用性、健壮的制造和表征协议。这项工作将建立针对弱免疫原性亚单位抗原的优越和持久的抗体反应，同时减少抗载体抗体反应。这个项目将进一步展示拟议的平台相对于野生型噬菌体和商业可获得的载体蛋白在增强针对目标抗原的免疫反应方面的表现。这一奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the contribution to the field of conjugate vaccines, which have made revolutionary and tremendous contributions to public health. When successfully developed, the proposed platform will be available for use by biotechnology and pharmaceutical companies to develop next-generation conjugate vaccines against a wide range of antigens, including cancer and emerging infectious diseases, for improved clinical outcomes. In addition to vaccines, the platform offers an excellent starting point for the generation of monoclonal antibodies for both basic scientific research and therapeutic application. This Small Business Innovation Research Phase II project aims to establish the applicability, robust manufacturing and characterization protocols of a proposed mutant bacteriophage based carrier platform. This work will establish superior and long-lasting antibody response against weakly immunogenic subunit antigens, while reducing the anti-carrier antibody responses. This project will advance the demonstration of the proposed platform's performance in boosting the immune responses against the target antigens, relative to that of the wild-type bacteriophage and commercially available carrier proteins.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.